CROs/Service Providers

ReSearch Pharmaceutical, Asklep create joint venture in Japan

Friday, March 29, 2013 03:03 PM

ReSearch Pharmaceutical Services (RPS), a global CRO, and Asklep, a Japanese CRO, have created a joint venture company (JVC) to deliver leading-edge R&D outsourcing solutions in Japan to the biopharmaceutical and medical device industries. 

More... »

PPD expands cGMP cell-based assay laboratory

Friday, March 29, 2013 02:14 PM

Pharmaceutical Product Development (PPD), a global CRO, is expanding itscGMP cell-based assay laboratory in Middleton, Wis., to meet the growing needs of clients seeking to validate bioassays for product release and stability testing of biological products, both as novel drugs and as biosimilars.

More... »

Nypro to establish medical device manufacturing facility in Ireland, create over 200 jobs

Friday, March 29, 2013 11:57 AM

Nypro Healthcare, a global solutions provider, plans to establish an additional state-of-the-art medical device manufacturing facility in Waterford, Ireland. This newly established facility will result in the creation of over 200 new high-quality jobs in phase I, which is expected to increase in subsequent years.

More... »

BBK Worldwide expands ownership from within

Monday, March 25, 2013 01:47 PM

In an industry increasingly defined by mergers and acquisitions, BBK Worldwide is bucking the trend by creating ownership opportunities from within.

More... »

Sanofi, Transgene form long-term collaboration for production of immunotherapy treatments

Monday, March 25, 2013 12:24 PM

Global healthcare company Sanofi and biopharmaceutical company Transgene have signed a collaboration agreement for the creation of a new state-of-the-art industrial platform dedicated to the production of immunotherapy products including Transgene's therapeutic products.

More... »

Benitec selects Duke Clinical Research Unit as a site for HCV phase I/II trial

Monday, March 25, 2013 11:03 AM

RNAi-based therapeutics company Benitec Biopharma has selected the Duke Clinical Research Unit, the early phase unit of the Duke Clinical Research Institute (DCRI) of Durham, N.C., as a site for its upcoming phase I/II first-in-man trial for TT-034 in hepatitis C (HCV). TT-034 is being developed as a potential "one-shot-cure" for HCV.

More... »

ShangPharma’s shareholders approve merger agreement

Monday, March 25, 2013 10:02 AM

China-based pharmaceutical and biotechnology R&D outsourcing company ShangPharma’s shareholders have voted in favor of merger agreement in which ShangPharma Merger Sub will merge with ShangPharma, with the new entity being a wholly owned subsidiary of ShangPharma Parent.

More... »

PRACS Institute closes; Chapter 7 imminent

Friday, March 22, 2013 01:23 PM

By Suz Redfearn
At 4:30 p.m. central time on Wednesday, March 20, the approximately 480 employees at PRACS Institute’s Fargo, N.D., facility—one of the largest phase I units in the world with 544 beds—were told via conference call that PRACS was shutting its doors, effective immediately.

More... »

Sotio selects Chiltern International for phase III trial

Monday, March 18, 2013 12:13 PM

Sotio, a Czech Republic-based biotechnology company developing a next generation Active Cellular Immunotherapy, has selected Chiltern International to be the CRO that carries out the European part of its phase III global clinical trial titled VIABLE, which will include 1,170 prostate cancer patients from Europe and the U.S.

More... »

Calvert Laboratories inks deal with Particle Sciences on early-stage development

Monday, March 18, 2013 11:53 AM

Calvert Laboratories and Particle Sciences, two CROs in the fields of preclinical toxicology and drug product formulation, have joined forces to offer a streamlined solution to expedite preclinical drug development activities. 

More... »